Medical device company LeMaitre Vascular (NASDAQ:LMAT) in Q4 CY2024, but sales rose 14% year on year to $55.72 million. Next ...

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations. Looking ...

Oppenheimer has downgraded LeMaitre Vascular (NASDAQ:LMAT) to perform from outperform as its price target of $93 has been met ...

Barrington analyst Michael Petusky downgraded LeMaitre (LMAT) to Market Perform from Outperform without a price target following the Q4 report.

Citizens JMP raised the firm’s price target on LeMaitre (LMAT) to $113 from $100 and keeps an Outperform rating on the shares. LeMaitre’s Q4 ...

Learn more about whether LeMaitre Vascular, Inc. or Teleflex Incorporated is a better investment based on AAII's A+ Investor ...

LeMaitre Vascular Inc (LMAT) reports robust sales growth and strategic global expansion, while navigating regulatory and ...

For the current quarter ending in March, LeMaitre said it expects revenue in the range of $56.7 million to $58.7 million. The company expects full-year earnings to be $2.15 to $2.32 per share, with ...

BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results ...

BURLINGTON, Mass. (AP) — BURLINGTON, Mass. (AP) — LeMaitre Vascular Inc. (LMAT) on Thursday reported fourth-quarter net income of $11.2 million. The Burlington, Massachusetts-based company ...

LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend ...